Bio Green Med Solution, Inc. (BGMS) Stock Price & Analysis
Bio Green Med Solution, Inc. (BGMS) — MoonshotScore 22/100 (Weak band), calculated Nov 18, 2026. Price $0.6109 (+1.82%), as of the Nov 19, 2026 trading session; market cap $4.05M.
Educational signal · not a buy or sell recommendation · How to read this
Bio Green Med Solution, Inc. · BGMS
Bio Green Med Solution, Inc. (BGMS) is a dual-industry company operating in both biopharmaceutical research and fire protection solutions. The company recently expanded its fire safety capabilities through the acquisition of Fitters Sdn. Bhd., a Malaysian firm.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Bio Green Med Solution (BGMS)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, at a cheap price, but bottom-tier quality. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Growing; Momentum: Slipping.
- quarterly revenue $336,000 (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 7 of the last 8 reports
- ROE -24.2% · ROA -22.2% · current ratio 6.84 · earnings yield -39.2% · free-cash-flow yield -26.9%
Holding back: weak fundamentals, weak price trend
Helping: an attractive price, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 21 | Weak | |
| 23 | Weak | |
| 23 | Weak | |
| 23 | Weak | |
| 22 | Weak | |
| 22 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.6109 | |
| Change on the day | +1.82% | |
| Market capitalisation | $4.05M | — |
| Shares traded on the day | 80.4K |
Price & events
Other perspectives
Council score for Bio Green Med Solution (BGMS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Oct 21, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Oct 21, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Bio Green Med Solution (BGMS), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Bio Green Med Solution, Inc. (BGMS) is the company analyzed here. In Q2 FY2026 it reported revenue of $336,000 and net income of -$405,000. The market values it at $4.05M.
What do the latest results show for Bio Green Med Solution (BGMS)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $336,000. Against analyst estimates the company has EPS beat 7 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $336,000 | -$405,000 | -$0.07 (diluted) |
| Q1 FY2026 | $778,000 | -$197,000 | -$0.04 (diluted) |
| Q4 FY2025 | $666,000 | -$611,000 | -$0.13 (diluted) |
| Q3 FY2025 | $81,000 | -$988,000 | -$0.52 (diluted) |
What are the financial strengths and risks for Bio Green Med Solution (BGMS)?
Short answer · as of
The MoonshotScore pillars rate an attractive price, durable growth as strengths. What is holding it back is weak fundamentals, weak price trend. The distress and quality screens read Piotroski F 4. Trailing ratios: ROE -24.2% · ROA -22.2% · current ratio 6.84 · earnings yield -39.2% · free-cash-flow yield -26.9%.
How does Bio Green Med Solution compare with its peers?
Short answer
Bio Green Med Solution's score ranks 2nd of 2 in the bounded comparison shown, against 1 same-model peer. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $169.03 Nov 19, 2026 | $7.07B | 90 5-pillar Nov 18, 2026 | |
| Bio Green Med Solution (BGMS) — this page | $0.6109 | $4.05M | 22 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 5
- Purchases
- 0
- Sales
- 1
- Other transactions
- 11
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BGMS in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BGMS in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Bio Green Med Solution (BGMS)?
Bio Green Med Solution Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the BGMS research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for BGMS?
BGMS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Bio Green Med Solution, Inc. (BGMS) is a dual-industry company operating in both biopharmaceutical research and fire protection solutions.
Is BGMS a good stock to buy?
Stock Expert AI does not rate BGMS buy, sell or hold. Bio Green Med Solution, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BGMS stock price today?
The last price recorded for Bio Green Med Solution, Inc. (BGMS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Bio Green Med Solution, Inc.'s acquisition of Fitters Sdn. Bhd. impact its business?
The acquisition of Fitters Sdn. Bhd. significantly impacts Bio Green Med Solution, Inc. by broadening its operational scope beyond biopharmaceuticals into the fire protection industry.
What are the key factors to evaluate for BGMS?
Bio Green Med Solution, Inc. (BGMS) holds a MoonshotScore in the low range. Recent acquisition of Fitters Sdn. Not financial advice.
How frequently does BGMS data refresh on this page?
BGMS's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BGMS's recent stock price performance?
Bio Green Med Solution, Inc. (BGMS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified business operations across biopharmaceuticals and fire protection, potentially mitigating sector-specific risks. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BGMS overvalued or undervalued right now?
Bio Green Med Solution, Inc. (BGMS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BGMS before investing?
Before investing in Bio Green Med Solution, Inc. (BGMS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 8 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com